William Espar, MD
Cardiovascular Disease · Michigan City, INNPI 1952396855
Payments from drug & device makers
Across 351 payments — averaging $25.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Novartis$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$483
- Johnson & Johnson$434
- Abbott$351
- Abiomed$346
- plus $2K from 31 others
What the payments were for
- Consulting fees$4855%
- Travel & lodging$2,03123%
- Food & beverage$6,40371%
- Education$971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 68 | $4,002 |
| Novartis | 85 | $1,109 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 32 | $483 |
| Johnson & Johnson | 28 | $434 |
| Abbott | 12 | $351 |
| Abiomed | 11 | $346 |
| Amgen | 15 | $276 |
| Pfizer | 13 | $196 |
| Actelion Pharmaceuticals US, Inc. | 6 | $187 |
| Merck | 7 | $167 |
| Boehringer Ingelheim | 9 | $160 |
| E.r. Squibb & Sons, L.L.C. | 10 | $145 |
| Sanofi-aventis U.S. LLC | 8 | $139 |
| Heartflow, Inc. | 5 | $139 |
| Penumbra, Inc. | 1 | $75 |
| Philips North America LLC | 3 | $71 |
| Gilead | 5 | $70 |
| AstraZeneca | 4 | $60 |
| Boston Scientific | 3 | $59 |
| Amarin Pharma, Inc. | 4 | $58 |
| Cook Medical LLC | 1 | $49 |
| Terumo Medical Corporation | 2 | $48 |
| Vital Connect, Inc | 2 | $46 |
| Cvrx, Inc. | 2 | $41 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Cardiovascular Systems Inc. | 2 | $27 |
| Shockwave Medical, Inc | 1 | $27 |
| Vifor Pharma, Inc. | 1 | $25 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Biosense Webster, Inc. | 1 | $23 |
| Edwards Lifesciences | 1 | $22 |
| Convatec Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Biotronik Inc. | 1 | $18 |
| BD | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ATTAIN COMMAND + SUREVALVE$1,147
- COREVALVE EVOLUT R$101
- Azure$100
How this compares
$9,015 in reported general payments places this provider in the 70th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 234 | $303,435 |
| XareltoRivaroxaban | 185 | $179,775 |
| EntrestoSacubitril/Valsartan | 75 | $89,568 |
| Repatha SureclickEvolocumab | 49 | $56,501 |
| BrilintaTicagrelor | 58 | $39,107 |
| JardianceEmpagliflozin | 15 | $18,654 |
| Prasugrel Hcl | 71 | $10,916 |
| Sildenafil Citrate | 15 | $6,846 |
| Ranolazine ErRanolazine | 74 | $5,957 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 207 | $5,467 |
| Metoprolol Succinate | 454 | $4,849 |
| Atorvastatin Calcium | 482 | $3,440 |
| PlavixClopidogrel Bisulfate | 11 | $2,609 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 216 | $2,460 |
| ClopidogrelClopidogrel Bisulfate | 195 | $2,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $196 | $303,435234 claims |
| Johnson & JohnsonXarelto | $434 | $179,775185 claims |
| NovartisEntresto | $1,109 | $89,56875 claims |
| AstraZenecaBrilinta | $60 | $39,10758 claims |
| Boehringer IngelheimJardiance | $160 | $18,65415 claims |
| Sanofi-aventis U.S. LLCPlavix | $139 | $2,60911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Michigan City
- John McGintyRichmond$3.7M
- Steven SteinhublLafayette$2.4M
- Ravi BhagwatMunster$2.2M
- Mohan KesaniMunster$1.2M
- Vijay MehtaElkhart$925K
- William CollisFort Wayne$842K
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
- Wail AsfourMunster$736K
- Vijay RaoIndianapolis$706K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.